SAGE
Sage Therapeutics, Inc. (SAGE) Scenario Analysis Analysis (2026)
Overall Score
Base Case
SAGE has a strong cash position and liquidity profile, with a current ratio of 9.16x and cash per share of 5.84.
The company still screens as unprofitable on a TTM basis, with negative operating margin (-2.66%) and negative free cash flow yield (-25.77%).
Valuation remains elevated on sales at 10.69x EV/Sales, which leaves limited margin for error despite the balance sheet strength.
Bull Case
A large cash balance and low leverage provide flexibility to fund development and absorb volatility.
Gross margin is extremely high at 98.69%, indicating strong underlying product economics if operating losses narrow.
If revenue scales and operating expenses normalize, the current liquidity cushion could support a rerating.
Bear Case
Persistent losses and negative cash generation remain the core downside risk, with ROE at -28.74% and ROIC at -31.78%.
High SG&A and R&D intensity continue to pressure profitability, with SG&A at 261.55% of revenue and R&D at 102.08% of revenue.
The stock could de-rate sharply if growth slows, since the valuation already assumes meaningful future improvement.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Sage Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

